UROGEN PHARMA LTD (URGN) Fundamental Analysis & Valuation

NASDAQ:URGN • IL0011407140

Current stock price

17.17 USD
-0.73 (-4.08%)
At close:
17.01 USD
-0.16 (-0.93%)
After Hours:

This URGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. URGN Profitability Analysis

1.1 Basic Checks

  • In the past year URGN has reported negative net income.
  • URGN had a negative operating cash flow in the past year.
  • In the past 5 years URGN always reported negative net income.
  • In the past 5 years URGN always reported negative operating cash flow.
URGN Yearly Net Income VS EBIT VS OCF VS FCFURGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • URGN's Return On Assets of -76.57% is on the low side compared to the rest of the industry. URGN is outperformed by 66.28% of its industry peers.
Industry RankSector Rank
ROA -76.57%
ROE N/A
ROIC N/A
ROA(3y)-59.44%
ROA(5y)-70.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
URGN Yearly ROA, ROE, ROICURGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K

1.3 Margins

  • With an excellent Gross Margin value of 88.66%, URGN belongs to the best of the industry, outperforming 90.56% of the companies in the same industry.
  • In the last couple of years the Gross Margin of URGN has remained more or less at the same level.
  • URGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y-0.62%
URGN Yearly Profit, Operating, Gross MarginsURGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K -300K -400K -500K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. URGN Health Analysis

2.1 Basic Checks

  • URGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for URGN has been increased compared to 1 year ago.
  • URGN has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for URGN is higher compared to a year ago.
URGN Yearly Shares OutstandingURGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
URGN Yearly Total Debt VS Total AssetsURGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -5.74, we must say that URGN is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -5.74, URGN is not doing good in the industry: 65.13% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.74
ROIC/WACCN/A
WACC7.93%
URGN Yearly LT Debt VS Equity VS FCFURGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

2.3 Liquidity

  • URGN has a Current Ratio of 4.01. This indicates that URGN is financially healthy and has no problem in meeting its short term obligations.
  • URGN has a Current ratio (4.01) which is in line with its industry peers.
  • URGN has a Quick Ratio of 3.65. This indicates that URGN is financially healthy and has no problem in meeting its short term obligations.
  • URGN's Quick ratio of 3.65 is in line compared to the rest of the industry. URGN outperforms 46.63% of its industry peers.
Industry RankSector Rank
Current Ratio 4.01
Quick Ratio 3.65
URGN Yearly Current Assets VS Current LiabilitesURGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. URGN Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 0.93% over the past year.
  • URGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.45%.
  • The Revenue has been growing by 56.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.5%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y19.48%
Revenue growth 5Y56.22%
Sales Q2Q%54.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.85% on average over the next years. This is a very strong growth
  • URGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.71% yearly.
EPS Next Y62.62%
EPS Next 2Y49.68%
EPS Next 3Y43.23%
EPS Next 5Y31.85%
Revenue Next Year118.57%
Revenue Next 2Y94.91%
Revenue Next 3Y69.54%
Revenue Next 5Y52.71%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
URGN Yearly Revenue VS EstimatesURGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
URGN Yearly EPS VS EstimatesURGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. URGN Valuation Analysis

4.1 Price/Earnings Ratio

  • URGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year URGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
URGN Price Earnings VS Forward Price EarningsURGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
URGN Per share dataURGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

  • URGN's earnings are expected to grow with 43.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.68%
EPS Next 3Y43.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. URGN Dividend Analysis

5.1 Amount

  • No dividends for URGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

URGN Fundamentals: All Metrics, Ratios and Statistics

UROGEN PHARMA LTD

NASDAQ:URGN (3/27/2026, 8:00:01 PM)

After market: 17.01 -0.16 (-0.93%)

17.17

-0.73 (-4.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-11
Inst Owners94.87%
Inst Owner Change-3.03%
Ins Owners2.1%
Ins Owner Change0.36%
Market Cap835.84M
Revenue(TTM)109.79M
Net Income(TTM)-153.49M
Analysts84.29
Price Target36.34 (111.65%)
Short Float %18.18%
Short Ratio10.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.52%
Min EPS beat(2)-5.36%
Max EPS beat(2)2.31%
EPS beat(4)1
Avg EPS beat(4)-9.81%
Min EPS beat(4)-23.47%
Max EPS beat(4)2.31%
EPS beat(8)2
Avg EPS beat(8)-3.9%
EPS beat(12)5
Avg EPS beat(12)0.12%
EPS beat(16)8
Avg EPS beat(16)0.71%
Revenue beat(2)0
Avg Revenue beat(2)-12.83%
Min Revenue beat(2)-18.58%
Max Revenue beat(2)-7.08%
Revenue beat(4)1
Avg Revenue beat(4)-8.99%
Min Revenue beat(4)-18.58%
Max Revenue beat(4)2.61%
Revenue beat(8)2
Avg Revenue beat(8)-8.05%
Revenue beat(12)5
Avg Revenue beat(12)-4.92%
Revenue beat(16)5
Avg Revenue beat(16)-6.43%
PT rev (1m)1.06%
PT rev (3m)1.06%
EPS NQ rev (1m)-7.73%
EPS NQ rev (3m)-7.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-62.61%
Revenue NQ rev (1m)-1.84%
Revenue NQ rev (3m)1.84%
Revenue NY rev (1m)3.56%
Revenue NY rev (3m)-3.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.61
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.2
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)-3.34
OCFYN/A
SpS2.26
BVpS-2.17
TBVpS-2.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.66%
FCFM N/A
ROA(3y)-59.44%
ROA(5y)-70.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y-0.62%
F-Score1
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 94.14%
Cap/Sales 0.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.01
Quick Ratio 3.65
Altman-Z -5.74
F-Score1
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)69.33%
Cap/Depr(5y)65.11%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.5%
EPS Next Y62.62%
EPS Next 2Y49.68%
EPS Next 3Y43.23%
EPS Next 5Y31.85%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y19.48%
Revenue growth 5Y56.22%
Sales Q2Q%54.03%
Revenue Next Year118.57%
Revenue Next 2Y94.91%
Revenue Next 3Y69.54%
Revenue Next 5Y52.71%
EBIT growth 1Y-29.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.15%
EBIT Next 3Y42.07%
EBIT Next 5YN/A
FCF growth 1Y-67.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.87%
OCF growth 3YN/A
OCF growth 5YN/A

UROGEN PHARMA LTD / URGN Fundamental Analysis FAQ

What is the fundamental rating for URGN stock?

ChartMill assigns a fundamental rating of 3 / 10 to URGN.


Can you provide the valuation status for UROGEN PHARMA LTD?

ChartMill assigns a valuation rating of 1 / 10 to UROGEN PHARMA LTD (URGN). This can be considered as Overvalued.


Can you provide the profitability details for UROGEN PHARMA LTD?

UROGEN PHARMA LTD (URGN) has a profitability rating of 1 / 10.